97 results
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
28 Jun 23
Atossa Therapeutics Announces $10M Stock Repurchase Program
9:01am
million of its common stock through December 31, 2023.
"We are committed to strategically deploying capital to drive long-term value for stockholders … value over the long term. The size of the repurchase authorization is less than 10% of total cash, as reported on March 31, 2023, and should not have
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
31 Mar 21
Atossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate Update
9:01am
current liabilities
Long term liabilities
Lease liability long term
Total Liabilities
Commitments and contingencies
Stockholders' equity
Preferred
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
13 Aug 19
Atossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company Update
8:33am
Total current liabilities
Long term liabilities
Lease liability long term
Total Liabilities
Commitments and contingencies
Stockholders' equity
Preferred
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
13 May 19
Atossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update
4:30pm
Long term liabilities
Lease liability long term
Total Liabilities
Commitments and contingencies
Stockholders' equity
Preferred stock - $0.001 par value
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
13 May 20
Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs
9:30am
Lease liability
Other current liabilities
Total current liabilities
Long term liabilities
Lease liability long term
Total Liabilities
Commitments
8-K
EX-99.1
fk236
26 Mar 20
Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update
8:05am
8-K
EX-99.1
52l92v59 m5ep7atz8
13 Nov 20
Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
9:30am
8-K
EX-99.1
qwgc2 z3tq9xj
13 Nov 19
Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update
9:03am
8-K
EX-99.1
y2917
13 Aug 20
Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update
9:30am
S-1/A
EX-10.17
yifmaemu0r4zgqyxn
23 Nov 10
IPO registration (amended)
12:00am
8-K
EX-99.1
533q8a13a6ajgx
27 Jun 19
Regulation FD Disclosure
12:48pm
DEF 14A
c1zt l4k1bb6w
15 Apr 13
Definitive proxy
12:00am
8-K
EX-99.1
7zf4orzj 6im8
13 Aug 21
Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting
9:30am
8-K
EX-99.2
okxl zok0kgumlq
4 Oct 13
Other Events
12:00am
8-K
EX-99.1
ico 3s1ejhxgb8
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
4:00pm
8-K
EX-99.2
64rllz0ba9rutx7
25 Oct 17
Atossa Genetics Announces Preliminary Results from
12:00am